Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Core Insights - Sanofi has announced an agreement to acquire Dynavax Technologies Corporation, enhancing its adult immunization portfolio with Dynavax's marketed adult hepatitis B vaccine and shingles vaccine candidate [1][2][3] Company Overview - Sanofi is a biopharmaceutical company focused on R&D and committed to improving lives through innovative medicines and vaccines [12] - Dynavax is a biopharmaceutical company that develops and commercializes vaccines to protect against infectious diseases, with its HEPLISAV-B vaccine approved in multiple regions [13] Acquisition Details - The acquisition involves a cash tender offer of $15.50 per share, valuing Dynavax at approximately $2.2 billion [4] - The transaction has received unanimous approval from Dynavax's board and is subject to customary closing conditions, including regulatory approvals [5][6] Product Information - HEPLISAV-B is a two-dose adult hepatitis B vaccine that offers faster seroprotection compared to traditional three-dose vaccines [2][8] - The shingles vaccine candidate Z-1018 is currently in phase 1/2 clinical development, adding to Dynavax's pipeline [2] Market Opportunity - There is a significant unmet health need for adult vaccinations, with nearly 100 million adults in the US born before 1991 remaining unvaccinated against hepatitis B [3] - Shingles affects one in three adults over their lifetime, highlighting the importance of vaccination in this demographic [3] Financial Impact - The acquisition is not expected to affect Sanofi's financial guidance for 2025 and is anticipated to close in the first quarter of 2026 [7]